Mara Soraya Rodriguez Evaristo

Dr. Mara Soraya Rodriguez Evaristo

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 September 2023 in International Journal of STD & AIDS
Verified
Journal Article
Closed access
JMJosé Antonio Mata Marín
José Antonio Mata Marín
JVJuan Carlos Velasco-Penagos
Juan Carlos Velasco-Penagos
SMStefan Mauss
Stefan Mauss
MEMara Soraya Rodriguez Evaristo
Mara Soraya Rodriguez Evaristo
EPEdgar Pérez-Barragán
Edgar Pérez-Barragán
JGJesús Enrique Gaytán-Martínez
Jesús Enrique Gaytán-Martínez
Background: People living with HIV (PLWH) starting or switching to an integrase strand transfer inhibitor-based regimen are more likely to experience weight gain than other classes of antiretroviral regimens. The aim of this study was to evaluate the weight gain and metabolic disturbances in PLWH who start antiretroviral therapy (ART) with bictegravir/emtricitabine/tenofovir alafenamide and in individuals who switch from another ART to BIC/FTC/TAF after 48 weeks. Methods: A prospective longitudinal study was conducted in an HIV clinic in Mexico. Weight and metabolic parameters were measured at baseline, 24 and 48 weeks. A paired t test and Wilcoxon signed-rank test were applied to evaluate weight and metabolic changes. Results: 160 participants completed measurements, median age was 29 (IQR 26-32) and 30 (IQR 27–34) years old for the treatment-naïve and switch group respectively. In the treatment-naïve group, mean weight change was 3.8 kg (±5.8) ( p < .001) and BMI increased 1.3 kg/m2 (±2) ( p < .001) at 48 weeks. Incidence of BMI >25 kg/m2 was 28% (95%CI; 18%–40%) and BMI >30 kg/m2 was 7% (95%CI; 2%–16%) at 48 weeks in treatment-naïve individuals. In the switch group, mean weight gain and BMI change at 48 weeks was 2.8 kg (±5.9) and 0.9 kg/m2 (±2.0) respectively ( p < .001). Incidence of BMI >25 kg/m2 was 17% (95%CI; 8%–32%) and BMI >30 kg/m2 12.8% (95%CI; 5%–26%) at 48 weeks respectively. Conclusions: Weight gain should be considered when men PLWH are treated with BIC/FTC/TAF regimen. They should be informed about this possible adverse event and strategies of intervention.

15 July 2022 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JMJosé Antonio Mata-Marín
José Antonio Mata-Marín
APArmando Abraham de Pablos-Leal
Armando Abraham de Pablos-Leal
SMStefan Mauss
Stefan Mauss
CACarla Ileana Arroyo-Anduiza
Carla Ileana Arroyo-Anduiza
MEMara Soraya Rodriguez Evaristo
Mara Soraya Rodriguez Evaristo
JGJesús Gaytán-Martínez
Jesús Gaytán-Martínez
Purpose: In the last two decades transmission of hepatitis C virus (HCV) in HIV positive men who have sex with men (MSM) has been reported globally. Chemsex and specific sexual practices have been identified as risk factors. Our study aimed to identify risk factors for HCV transmission in MSM living with HIV attending in Mexico. Methods: We conducted a case-control study from April to December 2019 at the Hospital de Infectología “La Raza” National Medical Center, in Mexico City. A case was defined as an HIV-infected MSM with positive HCV-antibody test. For each case, 3 controls were included, defined as HIV infected MSM with negative HCV-antibody test. A self-questionnaire covering sexual practices and other risk factors for HCV transmission was applied. Bivariate analysis was performed to obtain odds ratio (OR) using Chi-square test. Independent risk factors were identified in a subsequent analysis performing a logistic regression model. Results: A total of 324 patients participated in the study, 81 cases and 243 controls. Median age was 30.5 years (IQR: 18–52) and 28.8 years (IQR: 21–45) in the case and control group, respectively. Most prevalent HCV genotype was 1a (79%). In the logistic regression model, sharing straw during cocaine inhalation (OR: 9.03; 95% CI; 1.35–13.52; P = 0.003), sharing sex toys (OR: 17.53, 95% CI; 6.85–44.86; P = 0.002), and ethyl chloride use for chemsex (OR: 2.26; 95% CI; 1.29–5.56; P = 0.037) were significant risk factors for HCV infection. Conclusion: This study identifies risk factors for HCV transmission in Mexico in HIV positive MSM in congruence with the findings of many studies performed worldwide. This is the first study that indicates a possible association between ethyl chloride use in chemsex and HCV infection. Assessment of local populations for risk factors for HCV transmission may help to develop specifically targeted behavioral interventions to reduce HCV transmission.

1 January 2025 in Journal of the International Association of Providers of AIDS Care (JIAPAC)
Verified
Journal Article
Open access
JNJuan Pablo Sánchez Navarro
Juan Pablo Sánchez Navarro
GAGustavo Barriga Angulo
Gustavo Barriga Angulo
JMJOSE Antonio MATA MARIN
JOSE Antonio MATA MARIN
MEMara Soraya Rodriguez Evaristo
Mara Soraya Rodriguez Evaristo
PNPaola Edith Padilla Noguera
Paola Edith Padilla Noguera
JMJesús Enrique Gaytán Martínez
Jesús Enrique Gaytán Martínez
Background: The incidence of sexually transmitted infections (STIs) remains high among men who have sex with men (MSM) living with human immunodeficiency virus (HIV) (PWH). This study determined the prevalence of asymptomatic STIs in MSM PWH attending an HIV clinic in Mexico City. Methods: This cross-sectional study (May 2022-November 2023) included self-questionnaires on STI-related behaviors and symptoms, urethral samples for multiplex polymerase chain reaction (PCR), and serological tests for syphilis, HBV, and HCV. Results: Among 261 patients, 56.7% were receiving antiretroviral therapy, 41.8% had suppressed HIV-1 viral load, and 26.1% tested positive for at least one STI in urethral PCR. The most prevalent microorganisms were Ureaplasma urealyticum (14.9%), Mycoplasma hominis (6.9%), Mycoplasma genitalium (4.2%), and Chlamydia trachomatis (3.1%). Multiple infections were identified in 5.3% of cases. Seroprevalence rates for syphilis, HBV, and HCV were 17.6%, 6.5%, and 3.1%, respectively. Current smoking and insertive anal sex were the only statistically significant associated factors. Conclusions: This study underscores the high frequency of asymptomatic STIs and the importance of regular screening.

5 July 2024 in Viruses
Verified
Journal Article
Open access
PDF file
JMJOSE Antonio MATA MARIN
JOSE Antonio MATA MARIN
CJCarina Aurora Juárez-Contreras
Carina Aurora Juárez-Contreras
MEMara Soraya Rodriguez Evaristo
Mara Soraya Rodriguez Evaristo
OMOlivia Concepción Martínez-Carrizales
Olivia Concepción Martínez-Carrizales
Ericka Nelly Pompa-MeraEricka Nelly Pompa-Mera
Ericka Nelly Pompa-Mera
JGJesus Enrique Gaytan-Martínez
Jesus Enrique Gaytan-Martínez
Integrase strand transfer inhibitors (INSTI) are associated with neuropsychiatric adverse events (NPAEs). The aim of this study was to evaluate improvements in NPAEs after switching an INSTI-based regimen to darunavir/cobicistat (DRV/c) or doravirine (DOR). Methods: A prospective cohort study was conducted to evaluate the reversibility of NPAEs via the Patient Health Questionnaire (PHQ-9), the Insomnia Severity Index (ISI), and the Hospital Anxiety and Depression Scale (HADS-A and D) in patients who started antiretroviral therapy with dolutegravir (DTG) or bictegravir (BIC). These patients were switched to DRV/c or DOR. Scales were compared at the moment of the switch and 12 weeks later. Results: We included 1153 treatment-naïve men, 676 (58.7%) with BIC and 477 (41.3%) with DTG. A total of 32 (2.7%) experienced NPAEs that led to discontinuation. Insomnia was found in 20 patients; depression via PHQ-9 in 21 patients, via HADS-D in 5 patients, and anxiety via HADS-A in 12 patients. All of them were evaluated by a psychiatrist at the moment of the symptoms; 7 (21.8%) started psychotropic drugs. After 12 weeks of follow-up, PHQ-9, ISI, HADS-A, and HADS-D decreased, with a p-value ≤ 0.05. Conclusions: NPAEs seem to improve after switching to a DRV/c- or DOR-based regimen after the first 4 and 12 weeks.

4 June 2025 in AIDS
Verified
Journal Article
Closed access
JMJosé Antonio Mata Marín
José Antonio Mata Marín
MEMara Soraya Rodriguez Evaristo
Mara Soraya Rodriguez Evaristo
ADAna Luz Cano Díaz
Ana Luz Cano Díaz
GVGloria Elizabeth Salinas Velázquez
Gloria Elizabeth Salinas Velázquez
SGSalma Triana González
Salma Triana González
JMJesús Enrique Gaytán Martínez
Jesús Enrique Gaytán Martínez
Objective: Evidence suggests that patients initiating a second-generation integrase strand transfer inhibitors (INSTI)-based regimen may have a higher risk of developing metabolic syndrome (MetS) compared to those on other antiretroviral classes. This study aimed to describe the incidence of MetS at 48 weeks, based on ATP III criteria, in people with HIV (PWH) who started antiretroviral therapy (ART) with a DTG/ABC/3TC-based regimen compared to those receiving a BIC/TAF/FTC-based regimen. Design: A randomized, open-label clinical trial was conducted in PWH with no prior exposure to ART. Methods: Participants were randomized to receive either bictegravir/alafenamide tenofovir/emtricitabine (BIC/TAF/FTC) or dolutegravir/abacavir/lamivudine (DTG/ABC/3TC). Anthropometric measurements, including weight, height, blood pressure, waist circumference, bioelectrical impedance analysis, and visceral fat assessment via ultrasonography, were performed at baseline, 24 weeks, and 48 weeks. Metabolic parameters were evaluated at each visit. Results: Out of 378 subjects, 311 provided informed consent and were included. Of these, 276 completed 48 weeks of follow-up. The incidence of MetS was 6 (3.9%) and 10 (6.3%) in BIC/TAF/FTC and DTG/ABC/3TC arms, respectively, with no significant difference between groups. In the BIC/TAF/FTC group, 24 patients (9%) experienced a weight gain of ≥10%, compared to 16 patients (6%) in the DTG/ABC/3TC group (P = 0.72). Risk factors for MetS were age ≥40 years old, baseline BMI ≥25 kg/m2, and baseline visceral fat ≥5 cm prior to ART initiation. Conclusion: Incidence of MetS among PWH receiving an INSTI-based regimen was high, with no difference between BIC/TAF/FTC and DTG/ABC/3TC groups. Age, overweight and elevated visceral fat at baseline were all associated with MetS.

18 November 2025 in International Journal of STD & AIDS
Verified
Journal Article
Closed access
JMJosé Antonio Mata-Marín
José Antonio Mata-Marín
MEMara Soraya Rodriguez Evaristo
Mara Soraya Rodriguez Evaristo
ADAna Luz Cano Díaz
Ana Luz Cano Díaz
MVMaría del Rosario Valenzuela-Salazar
María del Rosario Valenzuela-Salazar
ACAlberto Chaparro-Sánchez
Alberto Chaparro-Sánchez
JGJesús Enrique Gaytán-Martínez
Jesús Enrique Gaytán-Martínez
Background: Integrase strand transfer inhibitor (INSTI)-based regimens, such as dolutegravir/lamivudine/abacavir (DTG/3TC/ABC) and bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF), are recommended as first-line antiretroviral therapy (ART) for people living with HIV (PLH). This study compares their efficacy and safety in ART-naïve men living with HIV (MLH) in a real-world setting over 48 weeks. Methods: This open-label, randomized clinical trial (February 2021–October 2024) at Hospital de Infectología “La Raza” enrolled ART-naïve MLH with HIV-1 RNA ≥500 copies/mL and creatinine clearance >30 mL/min. Participants were randomized 1:1 to BIC/FTC/TAF or DTG/3TC/ABC. The primary endpoint was undetectable viral load (<50 copies/mL) at week 48, with safety assessed by adverse events (AEs) per DAIDS criteria. Results: Of 311 participants, 153 received BIC/FTC/TAF and 158 DTG/3TC/ABC. Virologic suppression was achieved in 90% of the BIC/FTC/TAF group and 86% of the DTG/3TCC/ABC group (p = 0.32). Median CD4+ counts were 649 cells/µL (BIC/FTC/TAF) and 723 cells/µL (DTG/3 TC/ABC) (p = 0.18). DTG/3TC/ABC had higher gastrointestinal AEs (21.5% vs 14.3%; p = 0.04) and grade 3 neuropsychiatric AEs. BIC/FTC/TAF showed higher insomnia rates. Abacavir-related hypersensitivity occurred in 0.6%. Conclusion: Both regimens showed high efficacy. BIC/FTC/TAF was more effective in patients with low baseline CD4 + counts, while DTG/3TC/ABC performed better with higher viral loads. DTG/3TC/ABC had more neuropsychiatric AEs and rare hypersensitivity reactions.